基本情報
- 標準SMILES
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C- InChIKey
WMWTYOKRWGGJOA-CENSZEJFSA-N- 分子式
- C25H31F3O5S
- 平均分子量
- 500.6 g/mol
- 単同位体質量
- 500.18442975
概要
Fluticasone Propionate can cause developmental toxicity according to state or federal government labeling requirements.
名称と識別子
- 優先名称
- Fluticasone Propionate
- IUPAC
- [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
- 現地名
- プロピオン酸フルチカゾン
- 英語名
- Fluticasone propionate
- 分子式
- C25H31F3O5S
- 分子量
- 500.57
名称と別名
名称をさらに表示
データベース識別子
- CAS
80474-14-2- PubChem CID
- 444036
- DTXSID
DTXSID8045511- ChEMBL
CHEMBL1473- ChEBI
CHEBI:31441- UNII
- O2GMZ0LF5W
- EC Number
- 617-082-4
- Nikkaji
- J457.058H
物性
構造計算による物性
- XLogP
- 4
- 極性表面積
- 106 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 9
- 回転可能結合数
- 6
- 重原子数
- 34
- 形式電荷
- 0
- 複雑度
- 984
実験および物理化学的性質
Drugs
Pharmaceuticals -> Dermatologicals -> Corticosteroids, dermatological preparations
Pharmaceuticals -> Listed in ZINC15
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Pharmaceuticals
物理化学的性質
- 融点
- 275 °C · 275 °C
- 比旋光度
- 30 ° · D +30° (c = 0.35)
- 沸点
- 568.3 · 568.3±50.0 °C(Predicted)
- 比重(密度)
- 1.32 · 1.32±0.1 g/cm3(Predicted)
- 屈折率
- 31 ° · 31 ° (C=1, Dioxane)
- 貯蔵温度
- Store at RT
- 溶解性
- 10 · DMSO:「10」mg/mL
- 酸解離定数(Pka)
- 12.53 · 12.53±0.70(Predicted)
- 外見
- 個体
- 色
- 白い
- Merck
- 14 · 14,4211
- InChIKey
- WMWTYOKRWGGJOA-CENSZEJFSA-N
- SMILES
- [C@]1(C(=O)SCF)(OC(=O)CC)[C@H](C)C[C@@]2([H])[C@]3([H])C[C@@H](C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)F |&1:0,11,14,16,19,26,28,30,33,r|
- CAS データベース
- 80474 · 80474-14-2(CAS DataBase Reference)
- EPAの化学物質情報
- -1 · Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-,S-(fluoromethyl) ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)- (80474-14-2)
化学的性質
化学的特性Fluticasone propionate is a white to off-white powder with a molecular weight of 500.6, and 17 the empirical formula is C25H31F3O5S. It is practically insoluble in water, freely soluble in 18 dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol.
安全と法規制
GHS分類
GHS Classification
This chemical does not meet GHS hazard criteria for 10% (2 of 20) of reports.
Danger
H302 (20%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P233, P260, P261, P264, P270, P271, P272, P273, P280, P284, P301+P317, P302+P352, P304+P340, P318, P319, P321, P330, P333+P317, P342+P316, P362+P364, P391, P403, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 20 reports by companies from 17 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Regulatory Information
Hazard Traits - Developmental Toxicity
Fluticasone propionate: Does not have an individual approval but may be used under an appropriate group standard
安全データ
- wgk
- 2
- rtecs
- BV7980000
- 毒性
- LD50 oral in rat: > 2gm/kg
- hs_code
- 29372900
- safety_code
- 22-24/25
- Hazard Classifications
- Repr. 2STOT RE 2
- ストレージクラス
- 11 - Combustible Solids
化学と産業
薬理情報
FDA Pharmacological Classification
FLUTICASONE PROPIONATE
Corticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC]
ALLERGY RELIEF NASAL
Corticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC]
FLUTICASONE PROPIONATE NASAL
Corticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC]
MeSH Pharmacological Classification
Substances that reduce or suppress INFLAMMATION.
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
Absorption, Distribution and Excretion
Intranasal bioavailability of fluticasone propionate is <2%, and oral bioavailability is <1%. Intranasal exposure results in the majority of the dose being swallowed. Topical absorption of fluticasone propionate is very low but can change depending on a number of factors including integrity of the skin and the presence of inflammation or disease. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 9.0%.
Fluticasone propionate is mainly eliminated in the feces with <5% eliminated in the urine.
The volume of distribution of intravenous fluticasone propionate is 4.2L/kg. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration.
1093mL/min for fluticasone propionate. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration.
用途と製造
応用分野
用途吸入ステロイド薬気道の炎症を抑制し,喘息症状を改善する
使用Fluticasone Propionate is a derivative of Flumethasone, a glucocorticoid that has antiallergic, anti-asthmatic, and anti-inflammatory properties. It is used in the treatment of seasonal rhinitis and asthma. Compared to beclomethasone dipropionate, fluticasone propionate is reported to have a comparable side effect profile, but twice the activity in the treatment of asthma.
一般的な説明Fluticasone Propionate is the propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.
調製方法
製造方法Fluticasone propionate, synthesized by Glaxo Wellcome and launched in 1993, is a trifluorinated glucocorticosteroid. It shows good topical antiinflammatory activity and is commonly used as a safe and effective inhaled treatment for asthma and allergic rhinitis.Fluticasone propionate can be synthesized from 9 by using BrCH2F,2a ClCH2F,5a or S-(monofluoromethyl) diarylsulfonium tetrafluoroborate 5f,g directly. Using BrCH2F can get an ideal yield; however, BrCH2F is costly and will destroy to the ozone layer. In addition, 9 reacted with BrCH2Cl or Br2CH2 and then by an anion exchange with AgF,2c,5e KF, or tetrabutylammonium fluoride5b to afford 1 in a low yield.Improved Synthesis of Fluticasone Propionate
上流・下流製品情報
上流原料
サプライヤー50 社
補足説明
定義ChEBI: Fluticasone propionate is a trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity. It has a role as an anti-allergic agent, an anti-asthmatic drug, an anti-inflammatory drug, a dermatologic drug, a bronchodilator agent and an adrenergic agent. It is a corticosteroid, a steroid ester, an 11beta-hydroxy steroid, a propanoate ester, a fluorinated steroid, a thioester and a 3-oxo-Delta(1),Delta(4)-steroid. It derives from a fluticasone. It derives from a hydride of an androstane.
関連反応
関連ノート
読み込み中…